Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
08:01am, Wednesday, 15'th May 2024
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvoli
Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
10:56am, Thursday, 09'th May 2024
The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Monday, 06'th May 2024
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - En
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
08:01am, Wednesday, 17'th Apr 2024
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolv
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
10:36am, Tuesday, 09'th Apr 2024
The heavy selling pressure might have exhausted for Celldex (CLDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
01:01pm, Monday, 08'th Apr 2024
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
10:35am, Monday, 08'th Apr 2024
Celldex (CLDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
10:56am, Wednesday, 20'th Mar 2024
The consensus price target hints at a 71.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
07:00am, Friday, 08'th Mar 2024
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
10:30am, Tuesday, 05'th Mar 2024
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an “Infl
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten p
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
09:14pm, Thursday, 29'th Feb 2024
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Thursday, 29'th Feb 2024
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
10:56am, Thursday, 29'th Feb 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positi
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 28'th Feb 2024
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to mark
